nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS2—Risedronate—osteoporosis	0.304	1	CbGbCtD
Mesalazine—PPARG—periosteum—osteoporosis	0.00299	0.405	CbGeAlD
Mesalazine—PTGS2—periosteum—osteoporosis	0.00153	0.207	CbGeAlD
Mesalazine—IKBKB—uterus—osteoporosis	0.000658	0.0889	CbGeAlD
Mesalazine—ALOX5—bone marrow—osteoporosis	0.000463	0.0625	CbGeAlD
Mesalazine—PPARG—uterus—osteoporosis	0.000409	0.0553	CbGeAlD
Mesalazine—MPO—bone marrow—osteoporosis	0.000391	0.0529	CbGeAlD
Mesalazine—PPARG—bone marrow—osteoporosis	0.000347	0.047	CbGeAlD
Mesalazine—PTGS1—uterus—osteoporosis	0.000219	0.0296	CbGeAlD
Mesalazine—PTGS2—uterus—osteoporosis	0.000209	0.0283	CbGeAlD
Mesalazine—PTGS2—bone marrow—osteoporosis	0.000177	0.024	CbGeAlD
Mesalazine—Dry mouth—Zoledronate—osteoporosis	0.000163	0.000359	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000163	0.000359	CcSEcCtD
Mesalazine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000163	0.000358	CcSEcCtD
Mesalazine—Pruritus—Alendronate—osteoporosis	0.000163	0.000357	CcSEcCtD
Mesalazine—Dyspepsia—Risedronate—osteoporosis	0.000162	0.000357	CcSEcCtD
Mesalazine—Eye disorder—Estradiol—osteoporosis	0.000162	0.000357	CcSEcCtD
Mesalazine—Tinnitus—Estradiol—osteoporosis	0.000162	0.000356	CcSEcCtD
Mesalazine—Constipation—Ethinyl Estradiol—osteoporosis	0.000162	0.000355	CcSEcCtD
Mesalazine—Confusional state—Zoledronate—osteoporosis	0.000161	0.000355	CcSEcCtD
Mesalazine—Hypersensitivity—Calcitriol—osteoporosis	0.000161	0.000355	CcSEcCtD
Mesalazine—Cardiac disorder—Estradiol—osteoporosis	0.000161	0.000354	CcSEcCtD
Mesalazine—Arthralgia—Conjugated Estrogens—osteoporosis	0.000161	0.000353	CcSEcCtD
Mesalazine—Myalgia—Conjugated Estrogens—osteoporosis	0.000161	0.000353	CcSEcCtD
Mesalazine—Chest pain—Conjugated Estrogens—osteoporosis	0.000161	0.000353	CcSEcCtD
Mesalazine—Asthenia—Ibandronate—osteoporosis	0.000161	0.000353	CcSEcCtD
Mesalazine—Anxiety—Conjugated Estrogens—osteoporosis	0.00016	0.000352	CcSEcCtD
Mesalazine—Nausea—Etidronic acid—osteoporosis	0.00016	0.000352	CcSEcCtD
Mesalazine—Oedema—Zoledronate—osteoporosis	0.00016	0.000352	CcSEcCtD
Mesalazine—Anaphylactic shock—Zoledronate—osteoporosis	0.00016	0.000352	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00016	0.000351	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.00016	0.000351	CcSEcCtD
Mesalazine—Diarrhoea—Estropipate—osteoporosis	0.00016	0.000351	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Risedronate—osteoporosis	0.000159	0.00035	CcSEcCtD
Mesalazine—Infection—Zoledronate—osteoporosis	0.000159	0.00035	CcSEcCtD
Mesalazine—Fatigue—Risedronate—osteoporosis	0.000159	0.000349	CcSEcCtD
Mesalazine—Insomnia—Pamidronate—osteoporosis	0.000159	0.000348	CcSEcCtD
Mesalazine—Pruritus—Ibandronate—osteoporosis	0.000158	0.000348	CcSEcCtD
Mesalazine—Pain—Risedronate—osteoporosis	0.000158	0.000347	CcSEcCtD
Mesalazine—Constipation—Risedronate—osteoporosis	0.000158	0.000347	CcSEcCtD
Mesalazine—Angiopathy—Estradiol—osteoporosis	0.000158	0.000346	CcSEcCtD
Mesalazine—Shock—Zoledronate—osteoporosis	0.000158	0.000346	CcSEcCtD
Mesalazine—Paraesthesia—Pamidronate—osteoporosis	0.000157	0.000346	CcSEcCtD
Mesalazine—Diarrhoea—Alendronate—osteoporosis	0.000157	0.000346	CcSEcCtD
Mesalazine—Asthenia—Calcitriol—osteoporosis	0.000157	0.000345	CcSEcCtD
Mesalazine—Nervous system disorder—Zoledronate—osteoporosis	0.000157	0.000345	CcSEcCtD
Mesalazine—Immune system disorder—Estradiol—osteoporosis	0.000157	0.000345	CcSEcCtD
Mesalazine—Thrombocytopenia—Zoledronate—osteoporosis	0.000157	0.000345	CcSEcCtD
Mesalazine—Mediastinal disorder—Estradiol—osteoporosis	0.000157	0.000344	CcSEcCtD
Mesalazine—Dyspnoea—Pamidronate—osteoporosis	0.000156	0.000343	CcSEcCtD
Mesalazine—Tachycardia—Zoledronate—osteoporosis	0.000156	0.000343	CcSEcCtD
Mesalazine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000156	0.000343	CcSEcCtD
Mesalazine—Chills—Estradiol—osteoporosis	0.000156	0.000343	CcSEcCtD
Mesalazine—Somnolence—Pamidronate—osteoporosis	0.000156	0.000343	CcSEcCtD
Mesalazine—Skin disorder—Zoledronate—osteoporosis	0.000156	0.000342	CcSEcCtD
Mesalazine—Pruritus—Calcitriol—osteoporosis	0.000155	0.000341	CcSEcCtD
Mesalazine—Hyperhidrosis—Zoledronate—osteoporosis	0.000155	0.00034	CcSEcCtD
Mesalazine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000155	0.00034	CcSEcCtD
Mesalazine—Diarrhoea—Raloxifene—osteoporosis	0.000155	0.00034	CcSEcCtD
Mesalazine—Dyspepsia—Pamidronate—osteoporosis	0.000154	0.000339	CcSEcCtD
Mesalazine—Dizziness—Estropipate—osteoporosis	0.000154	0.000339	CcSEcCtD
Mesalazine—Oedema—Conjugated Estrogens—osteoporosis	0.000154	0.000339	CcSEcCtD
Mesalazine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000154	0.000339	CcSEcCtD
Mesalazine—Alopecia—Estradiol—osteoporosis	0.000154	0.000337	CcSEcCtD
Mesalazine—Infection—Conjugated Estrogens—osteoporosis	0.000153	0.000337	CcSEcCtD
Mesalazine—Diarrhoea—Ibandronate—osteoporosis	0.000153	0.000336	CcSEcCtD
Mesalazine—Anorexia—Zoledronate—osteoporosis	0.000153	0.000335	CcSEcCtD
Mesalazine—Decreased appetite—Pamidronate—osteoporosis	0.000152	0.000335	CcSEcCtD
Mesalazine—Mental disorder—Estradiol—osteoporosis	0.000152	0.000334	CcSEcCtD
Mesalazine—Dizziness—Alendronate—osteoporosis	0.000152	0.000334	CcSEcCtD
Mesalazine—Shock—Conjugated Estrogens—osteoporosis	0.000152	0.000333	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000151	0.000333	CcSEcCtD
Mesalazine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000151	0.000332	CcSEcCtD
Mesalazine—Erythema—Estradiol—osteoporosis	0.000151	0.000332	CcSEcCtD
Mesalazine—Fatigue—Pamidronate—osteoporosis	0.000151	0.000332	CcSEcCtD
Mesalazine—Gastrointestinal pain—Risedronate—osteoporosis	0.000151	0.000331	CcSEcCtD
Mesalazine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000151	0.000331	CcSEcCtD
Mesalazine—Urticaria—Ethinyl Estradiol—osteoporosis	0.00015	0.00033	CcSEcCtD
Mesalazine—Constipation—Pamidronate—osteoporosis	0.00015	0.000329	CcSEcCtD
Mesalazine—Pain—Pamidronate—osteoporosis	0.00015	0.000329	CcSEcCtD
Mesalazine—Diarrhoea—Calcitriol—osteoporosis	0.00015	0.000329	CcSEcCtD
Mesalazine—Skin disorder—Conjugated Estrogens—osteoporosis	0.00015	0.000329	CcSEcCtD
Mesalazine—Hypotension—Zoledronate—osteoporosis	0.00015	0.000329	CcSEcCtD
Mesalazine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.00015	0.000329	CcSEcCtD
Mesalazine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.00015	0.000329	CcSEcCtD
Mesalazine—Dizziness—Raloxifene—osteoporosis	0.00015	0.000328	CcSEcCtD
Mesalazine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000149	0.000328	CcSEcCtD
Mesalazine—Flatulence—Estradiol—osteoporosis	0.000149	0.000327	CcSEcCtD
Mesalazine—Tension—Estradiol—osteoporosis	0.000148	0.000326	CcSEcCtD
Mesalazine—Vomiting—Estropipate—osteoporosis	0.000148	0.000326	CcSEcCtD
Mesalazine—Dysgeusia—Estradiol—osteoporosis	0.000148	0.000325	CcSEcCtD
Mesalazine—Dizziness—Ibandronate—osteoporosis	0.000148	0.000325	CcSEcCtD
Mesalazine—Rash—Estropipate—osteoporosis	0.000147	0.000323	CcSEcCtD
Mesalazine—Dermatitis—Estropipate—osteoporosis	0.000147	0.000323	CcSEcCtD
Mesalazine—Anorexia—Conjugated Estrogens—osteoporosis	0.000147	0.000323	CcSEcCtD
Mesalazine—Nervousness—Estradiol—osteoporosis	0.000147	0.000323	CcSEcCtD
Mesalazine—Urticaria—Risedronate—osteoporosis	0.000147	0.000322	CcSEcCtD
Mesalazine—Back pain—Estradiol—osteoporosis	0.000146	0.000321	CcSEcCtD
Mesalazine—Headache—Estropipate—osteoporosis	0.000146	0.000321	CcSEcCtD
Mesalazine—Vomiting—Alendronate—osteoporosis	0.000146	0.000321	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000146	0.000321	CcSEcCtD
Mesalazine—Abdominal pain—Risedronate—osteoporosis	0.000146	0.00032	CcSEcCtD
Mesalazine—Body temperature increased—Risedronate—osteoporosis	0.000146	0.00032	CcSEcCtD
Mesalazine—Muscle spasms—Estradiol—osteoporosis	0.000145	0.000319	CcSEcCtD
Mesalazine—Rash—Alendronate—osteoporosis	0.000145	0.000318	CcSEcCtD
Mesalazine—Insomnia—Zoledronate—osteoporosis	0.000145	0.000318	CcSEcCtD
Mesalazine—Dermatitis—Alendronate—osteoporosis	0.000145	0.000318	CcSEcCtD
Mesalazine—Feeling abnormal—Pamidronate—osteoporosis	0.000144	0.000317	CcSEcCtD
Mesalazine—Hypotension—Conjugated Estrogens—osteoporosis	0.000144	0.000317	CcSEcCtD
Mesalazine—Headache—Alendronate—osteoporosis	0.000144	0.000316	CcSEcCtD
Mesalazine—Paraesthesia—Zoledronate—osteoporosis	0.000144	0.000316	CcSEcCtD
Mesalazine—Vomiting—Raloxifene—osteoporosis	0.000144	0.000316	CcSEcCtD
Mesalazine—Gastrointestinal pain—Pamidronate—osteoporosis	0.000143	0.000315	CcSEcCtD
Mesalazine—Dyspnoea—Zoledronate—osteoporosis	0.000143	0.000314	CcSEcCtD
Mesalazine—Rash—Raloxifene—osteoporosis	0.000143	0.000313	CcSEcCtD
Mesalazine—Dermatitis—Raloxifene—osteoporosis	0.000142	0.000313	CcSEcCtD
Mesalazine—Somnolence—Zoledronate—osteoporosis	0.000142	0.000313	CcSEcCtD
Mesalazine—Vomiting—Ibandronate—osteoporosis	0.000142	0.000313	CcSEcCtD
Mesalazine—Tremor—Estradiol—osteoporosis	0.000142	0.000311	CcSEcCtD
Mesalazine—Headache—Raloxifene—osteoporosis	0.000142	0.000311	CcSEcCtD
Mesalazine—Rash—Ibandronate—osteoporosis	0.000141	0.00031	CcSEcCtD
Mesalazine—Dermatitis—Ibandronate—osteoporosis	0.000141	0.00031	CcSEcCtD
Mesalazine—Dyspepsia—Zoledronate—osteoporosis	0.000141	0.00031	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000141	0.000309	CcSEcCtD
Mesalazine—Ill-defined disorder—Estradiol—osteoporosis	0.00014	0.000308	CcSEcCtD
Mesalazine—Headache—Ibandronate—osteoporosis	0.00014	0.000308	CcSEcCtD
Mesalazine—Insomnia—Conjugated Estrogens—osteoporosis	0.000139	0.000306	CcSEcCtD
Mesalazine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000139	0.000306	CcSEcCtD
Mesalazine—Vomiting—Calcitriol—osteoporosis	0.000139	0.000306	CcSEcCtD
Mesalazine—Decreased appetite—Zoledronate—osteoporosis	0.000139	0.000306	CcSEcCtD
Mesalazine—Nausea—Estropipate—osteoporosis	0.000139	0.000305	CcSEcCtD
Mesalazine—Body temperature increased—Pamidronate—osteoporosis	0.000139	0.000305	CcSEcCtD
Mesalazine—Abdominal pain—Pamidronate—osteoporosis	0.000139	0.000305	CcSEcCtD
Mesalazine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000138	0.000304	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000138	0.000304	CcSEcCtD
Mesalazine—Angioedema—Estradiol—osteoporosis	0.000138	0.000304	CcSEcCtD
Mesalazine—Rash—Calcitriol—osteoporosis	0.000138	0.000304	CcSEcCtD
Mesalazine—Fatigue—Zoledronate—osteoporosis	0.000138	0.000303	CcSEcCtD
Mesalazine—Dermatitis—Calcitriol—osteoporosis	0.000138	0.000303	CcSEcCtD
Mesalazine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000137	0.000302	CcSEcCtD
Mesalazine—Headache—Calcitriol—osteoporosis	0.000137	0.000302	CcSEcCtD
Mesalazine—Somnolence—Conjugated Estrogens—osteoporosis	0.000137	0.000301	CcSEcCtD
Mesalazine—Constipation—Zoledronate—osteoporosis	0.000137	0.000301	CcSEcCtD
Mesalazine—Pain—Zoledronate—osteoporosis	0.000137	0.000301	CcSEcCtD
Mesalazine—Nausea—Alendronate—osteoporosis	0.000137	0.0003	CcSEcCtD
Mesalazine—Malaise—Estradiol—osteoporosis	0.000136	0.0003	CcSEcCtD
Mesalazine—Hypersensitivity—Risedronate—osteoporosis	0.000136	0.000299	CcSEcCtD
Mesalazine—Vertigo—Estradiol—osteoporosis	0.000136	0.000299	CcSEcCtD
Mesalazine—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000136	0.000298	CcSEcCtD
Mesalazine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000136	0.000298	CcSEcCtD
Mesalazine—Syncope—Estradiol—osteoporosis	0.000136	0.000298	CcSEcCtD
Mesalazine—Nausea—Raloxifene—osteoporosis	0.000134	0.000295	CcSEcCtD
Mesalazine—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000134	0.000295	CcSEcCtD
Mesalazine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000134	0.000294	CcSEcCtD
Mesalazine—Palpitations—Estradiol—osteoporosis	0.000134	0.000294	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000133	0.000293	CcSEcCtD
Mesalazine—Fatigue—Conjugated Estrogens—osteoporosis	0.000133	0.000292	CcSEcCtD
Mesalazine—Nausea—Ibandronate—osteoporosis	0.000133	0.000292	CcSEcCtD
Mesalazine—Loss of consciousness—Estradiol—osteoporosis	0.000133	0.000292	CcSEcCtD
Mesalazine—Asthenia—Risedronate—osteoporosis	0.000132	0.000291	CcSEcCtD
Mesalazine—Feeling abnormal—Zoledronate—osteoporosis	0.000132	0.00029	CcSEcCtD
Mesalazine—Cough—Estradiol—osteoporosis	0.000132	0.00029	CcSEcCtD
Mesalazine—Pain—Conjugated Estrogens—osteoporosis	0.000132	0.00029	CcSEcCtD
Mesalazine—Constipation—Conjugated Estrogens—osteoporosis	0.000132	0.00029	CcSEcCtD
Mesalazine—Gastrointestinal pain—Zoledronate—osteoporosis	0.000131	0.000288	CcSEcCtD
Mesalazine—Hypertension—Estradiol—osteoporosis	0.000131	0.000287	CcSEcCtD
Mesalazine—Pruritus—Risedronate—osteoporosis	0.00013	0.000287	CcSEcCtD
Mesalazine—Nausea—Calcitriol—osteoporosis	0.00013	0.000286	CcSEcCtD
Mesalazine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000129	0.000284	CcSEcCtD
Mesalazine—Hypersensitivity—Pamidronate—osteoporosis	0.000129	0.000284	CcSEcCtD
Mesalazine—Chest pain—Estradiol—osteoporosis	0.000129	0.000283	CcSEcCtD
Mesalazine—Arthralgia—Estradiol—osteoporosis	0.000129	0.000283	CcSEcCtD
Mesalazine—Myalgia—Estradiol—osteoporosis	0.000129	0.000283	CcSEcCtD
Mesalazine—Anxiety—Estradiol—osteoporosis	0.000128	0.000282	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000128	0.000281	CcSEcCtD
Mesalazine—Urticaria—Zoledronate—osteoporosis	0.000127	0.00028	CcSEcCtD
Mesalazine—Discomfort—Estradiol—osteoporosis	0.000127	0.00028	CcSEcCtD
Mesalazine—Abdominal pain—Zoledronate—osteoporosis	0.000127	0.000278	CcSEcCtD
Mesalazine—Body temperature increased—Zoledronate—osteoporosis	0.000127	0.000278	CcSEcCtD
Mesalazine—Diarrhoea—Risedronate—osteoporosis	0.000126	0.000277	CcSEcCtD
Mesalazine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000126	0.000277	CcSEcCtD
Mesalazine—Dry mouth—Estradiol—osteoporosis	0.000126	0.000277	CcSEcCtD
Mesalazine—Asthenia—Pamidronate—osteoporosis	0.000126	0.000276	CcSEcCtD
Mesalazine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000125	0.000275	CcSEcCtD
Mesalazine—Confusional state—Estradiol—osteoporosis	0.000124	0.000273	CcSEcCtD
Mesalazine—Pruritus—Pamidronate—osteoporosis	0.000124	0.000273	CcSEcCtD
Mesalazine—Oedema—Estradiol—osteoporosis	0.000123	0.000271	CcSEcCtD
Mesalazine—Anaphylactic shock—Estradiol—osteoporosis	0.000123	0.000271	CcSEcCtD
Mesalazine—Infection—Estradiol—osteoporosis	0.000123	0.000269	CcSEcCtD
Mesalazine—Urticaria—Conjugated Estrogens—osteoporosis	0.000123	0.000269	CcSEcCtD
Mesalazine—Dizziness—Risedronate—osteoporosis	0.000122	0.000268	CcSEcCtD
Mesalazine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000122	0.000268	CcSEcCtD
Mesalazine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000122	0.000268	CcSEcCtD
Mesalazine—Shock—Estradiol—osteoporosis	0.000121	0.000267	CcSEcCtD
Mesalazine—Nervous system disorder—Estradiol—osteoporosis	0.000121	0.000266	CcSEcCtD
Mesalazine—Tachycardia—Estradiol—osteoporosis	0.00012	0.000265	CcSEcCtD
Mesalazine—Vomiting—Ethinyl Estradiol—osteoporosis	0.00012	0.000264	CcSEcCtD
Mesalazine—Diarrhoea—Pamidronate—osteoporosis	0.00012	0.000264	CcSEcCtD
Mesalazine—Skin disorder—Estradiol—osteoporosis	0.00012	0.000263	CcSEcCtD
Mesalazine—Hyperhidrosis—Estradiol—osteoporosis	0.000119	0.000262	CcSEcCtD
Mesalazine—Rash—Ethinyl Estradiol—osteoporosis	0.000119	0.000262	CcSEcCtD
Mesalazine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000119	0.000262	CcSEcCtD
Mesalazine—Headache—Ethinyl Estradiol—osteoporosis	0.000119	0.00026	CcSEcCtD
Mesalazine—Hypersensitivity—Zoledronate—osteoporosis	0.000118	0.000259	CcSEcCtD
Mesalazine—Vomiting—Risedronate—osteoporosis	0.000117	0.000258	CcSEcCtD
Mesalazine—Rash—Risedronate—osteoporosis	0.000116	0.000256	CcSEcCtD
Mesalazine—Dermatitis—Risedronate—osteoporosis	0.000116	0.000255	CcSEcCtD
Mesalazine—Dizziness—Pamidronate—osteoporosis	0.000116	0.000255	CcSEcCtD
Mesalazine—Headache—Risedronate—osteoporosis	0.000116	0.000254	CcSEcCtD
Mesalazine—Asthenia—Zoledronate—osteoporosis	0.000115	0.000252	CcSEcCtD
Mesalazine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000114	0.00025	CcSEcCtD
Mesalazine—Pruritus—Zoledronate—osteoporosis	0.000113	0.000249	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000112	0.000247	CcSEcCtD
Mesalazine—Nausea—Ethinyl Estradiol—osteoporosis	0.000112	0.000247	CcSEcCtD
Mesalazine—Insomnia—Estradiol—osteoporosis	0.000112	0.000245	CcSEcCtD
Mesalazine—Vomiting—Pamidronate—osteoporosis	0.000111	0.000245	CcSEcCtD
Mesalazine—Paraesthesia—Estradiol—osteoporosis	0.000111	0.000244	CcSEcCtD
Mesalazine—Asthenia—Conjugated Estrogens—osteoporosis	0.000111	0.000243	CcSEcCtD
Mesalazine—Rash—Pamidronate—osteoporosis	0.000111	0.000243	CcSEcCtD
Mesalazine—Dermatitis—Pamidronate—osteoporosis	0.00011	0.000243	CcSEcCtD
Mesalazine—Dyspnoea—Estradiol—osteoporosis	0.00011	0.000242	CcSEcCtD
Mesalazine—Headache—Pamidronate—osteoporosis	0.00011	0.000241	CcSEcCtD
Mesalazine—Somnolence—Estradiol—osteoporosis	0.00011	0.000241	CcSEcCtD
Mesalazine—Diarrhoea—Zoledronate—osteoporosis	0.00011	0.000241	CcSEcCtD
Mesalazine—Nausea—Risedronate—osteoporosis	0.00011	0.000241	CcSEcCtD
Mesalazine—Pruritus—Conjugated Estrogens—osteoporosis	0.000109	0.00024	CcSEcCtD
Mesalazine—Dyspepsia—Estradiol—osteoporosis	0.000109	0.000239	CcSEcCtD
Mesalazine—Decreased appetite—Estradiol—osteoporosis	0.000107	0.000236	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000107	0.000234	CcSEcCtD
Mesalazine—Fatigue—Estradiol—osteoporosis	0.000106	0.000234	CcSEcCtD
Mesalazine—Dizziness—Zoledronate—osteoporosis	0.000106	0.000233	CcSEcCtD
Mesalazine—Constipation—Estradiol—osteoporosis	0.000106	0.000232	CcSEcCtD
Mesalazine—Pain—Estradiol—osteoporosis	0.000106	0.000232	CcSEcCtD
Mesalazine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000106	0.000232	CcSEcCtD
Mesalazine—Nausea—Pamidronate—osteoporosis	0.000104	0.000229	CcSEcCtD
Mesalazine—Dizziness—Conjugated Estrogens—osteoporosis	0.000102	0.000224	CcSEcCtD
Mesalazine—Vomiting—Zoledronate—osteoporosis	0.000102	0.000224	CcSEcCtD
Mesalazine—Feeling abnormal—Estradiol—osteoporosis	0.000102	0.000223	CcSEcCtD
Mesalazine—Rash—Zoledronate—osteoporosis	0.000101	0.000222	CcSEcCtD
Mesalazine—Gastrointestinal pain—Estradiol—osteoporosis	0.000101	0.000222	CcSEcCtD
Mesalazine—Dermatitis—Zoledronate—osteoporosis	0.000101	0.000222	CcSEcCtD
Mesalazine—Headache—Zoledronate—osteoporosis	0.0001	0.00022	CcSEcCtD
Mesalazine—Vomiting—Conjugated Estrogens—osteoporosis	9.81e-05	0.000215	CcSEcCtD
Mesalazine—Urticaria—Estradiol—osteoporosis	9.81e-05	0.000215	CcSEcCtD
Mesalazine—Body temperature increased—Estradiol—osteoporosis	9.76e-05	0.000214	CcSEcCtD
Mesalazine—Abdominal pain—Estradiol—osteoporosis	9.76e-05	0.000214	CcSEcCtD
Mesalazine—Rash—Conjugated Estrogens—osteoporosis	9.72e-05	0.000214	CcSEcCtD
Mesalazine—Dermatitis—Conjugated Estrogens—osteoporosis	9.71e-05	0.000213	CcSEcCtD
Mesalazine—Headache—Conjugated Estrogens—osteoporosis	9.66e-05	0.000212	CcSEcCtD
Mesalazine—Nausea—Zoledronate—osteoporosis	9.51e-05	0.000209	CcSEcCtD
Mesalazine—Nausea—Conjugated Estrogens—osteoporosis	9.16e-05	0.000201	CcSEcCtD
Mesalazine—Hypersensitivity—Estradiol—osteoporosis	9.09e-05	0.0002	CcSEcCtD
Mesalazine—Asthenia—Estradiol—osteoporosis	8.86e-05	0.000195	CcSEcCtD
Mesalazine—Pruritus—Estradiol—osteoporosis	8.73e-05	0.000192	CcSEcCtD
Mesalazine—Diarrhoea—Estradiol—osteoporosis	8.45e-05	0.000186	CcSEcCtD
Mesalazine—Dizziness—Estradiol—osteoporosis	8.16e-05	0.000179	CcSEcCtD
Mesalazine—Vomiting—Estradiol—osteoporosis	7.85e-05	0.000172	CcSEcCtD
Mesalazine—Rash—Estradiol—osteoporosis	7.78e-05	0.000171	CcSEcCtD
Mesalazine—Dermatitis—Estradiol—osteoporosis	7.78e-05	0.000171	CcSEcCtD
Mesalazine—Headache—Estradiol—osteoporosis	7.73e-05	0.00017	CcSEcCtD
Mesalazine—Nausea—Estradiol—osteoporosis	7.33e-05	0.000161	CcSEcCtD
Mesalazine—PPARG—Metabolism—TPI1—osteoporosis	7.29e-05	0.000312	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CA2—osteoporosis	7.25e-05	0.00031	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—OXCT1—osteoporosis	7.25e-05	0.00031	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—IL6—osteoporosis	7.25e-05	0.00031	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AGER—osteoporosis	7.24e-05	0.00031	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RAP1A—osteoporosis	7.21e-05	0.000309	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—ADCY5—osteoporosis	7.21e-05	0.000309	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—IL6—osteoporosis	7.2e-05	0.000308	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MGLL—osteoporosis	7.18e-05	0.000307	CbGpPWpGaD
Mesalazine—CHUK—Disease—NFATC1—osteoporosis	7.17e-05	0.000307	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTSK—osteoporosis	7.15e-05	0.000306	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—IL6—osteoporosis	7.12e-05	0.000304	CbGpPWpGaD
Mesalazine—CHUK—Toll-Like Receptors Cascades—IL6—osteoporosis	7.12e-05	0.000304	CbGpPWpGaD
Mesalazine—CHUK—Disease—DKK1—osteoporosis	7.11e-05	0.000304	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MGLL—osteoporosis	7.06e-05	0.000302	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NFATC1—osteoporosis	7.04e-05	0.000301	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL1B—osteoporosis	7.02e-05	0.0003	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LRP5—osteoporosis	7.01e-05	0.0003	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TNF—osteoporosis	6.95e-05	0.000297	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	6.92e-05	0.000296	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—P4HB—osteoporosis	6.85e-05	0.000293	CbGpPWpGaD
Mesalazine—CHUK—Disease—WNT1—osteoporosis	6.85e-05	0.000293	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—CYP19A1—osteoporosis	6.84e-05	0.000293	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—IL6—osteoporosis	6.81e-05	0.000291	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ATIC—osteoporosis	6.77e-05	0.00029	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PNP—osteoporosis	6.77e-05	0.00029	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GAPDH—osteoporosis	6.73e-05	0.000288	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—PSMA2—osteoporosis	6.71e-05	0.000287	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—PSMA5—osteoporosis	6.71e-05	0.000287	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—IL6—osteoporosis	6.7e-05	0.000287	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LRP6—osteoporosis	6.7e-05	0.000287	CbGpPWpGaD
Mesalazine—CHUK—Disease—FGA—osteoporosis	6.66e-05	0.000285	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	6.66e-05	0.000285	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AGER—osteoporosis	6.56e-05	0.000281	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—RAP1A—osteoporosis	6.55e-05	0.00028	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—ADCY5—osteoporosis	6.54e-05	0.00028	CbGpPWpGaD
Mesalazine—PTGS2—Disease—LRP5—osteoporosis	6.54e-05	0.00028	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—IL6—osteoporosis	6.53e-05	0.000279	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—MYC—osteoporosis	6.47e-05	0.000277	CbGpPWpGaD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—IL6—osteoporosis	6.45e-05	0.000276	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TGFB1—osteoporosis	6.45e-05	0.000276	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—IL6—osteoporosis	6.4e-05	0.000274	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—IL6—osteoporosis	6.37e-05	0.000272	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL1B—osteoporosis	6.37e-05	0.000272	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—IL6—osteoporosis	6.34e-05	0.000271	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PSMA2—osteoporosis	6.34e-05	0.000271	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PSMA5—osteoporosis	6.34e-05	0.000271	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IRS2—osteoporosis	6.31e-05	0.00027	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—IL6—osteoporosis	6.31e-05	0.00027	CbGpPWpGaD
Mesalazine—PTGS2—Disease—LRP6—osteoporosis	6.25e-05	0.000267	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6R—osteoporosis	6.24e-05	0.000267	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TLN1—osteoporosis	6.24e-05	0.000267	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—IL6—osteoporosis	6.15e-05	0.000263	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—IRS2—osteoporosis	6.06e-05	0.000259	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TNF—osteoporosis	6.02e-05	0.000258	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—IDH2—osteoporosis	6.01e-05	0.000257	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RPL24—osteoporosis	6.01e-05	0.000257	CbGpPWpGaD
Mesalazine—PTGS2—Disease—LTF—osteoporosis	6.01e-05	0.000257	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—ESR2—osteoporosis	6e-05	0.000257	CbGpPWpGaD
Mesalazine—CHUK—Disease—ENO1—osteoporosis	5.94e-05	0.000254	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—IL6—osteoporosis	5.93e-05	0.000254	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	5.93e-05	0.000254	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—IL6—osteoporosis	5.93e-05	0.000254	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—IL6—osteoporosis	5.88e-05	0.000252	CbGpPWpGaD
Mesalazine—CHUK—Disease—PSMA2—osteoporosis	5.85e-05	0.00025	CbGpPWpGaD
Mesalazine—CHUK—Disease—PSMA5—osteoporosis	5.85e-05	0.00025	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—IL6—osteoporosis	5.83e-05	0.000249	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—IL6—osteoporosis	5.8e-05	0.000248	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—OXCT1—osteoporosis	5.75e-05	0.000246	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CA2—osteoporosis	5.75e-05	0.000246	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PSMA2—osteoporosis	5.75e-05	0.000246	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PSMA5—osteoporosis	5.75e-05	0.000246	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IRS2—osteoporosis	5.72e-05	0.000245	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.71e-05	0.000244	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—IL6—osteoporosis	5.71e-05	0.000244	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TLN1—osteoporosis	5.66e-05	0.000242	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP27A1—osteoporosis	5.65e-05	0.000242	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MGLL—osteoporosis	5.61e-05	0.00024	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—ADCY5—osteoporosis	5.59e-05	0.000239	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—GPX1—osteoporosis	5.57e-05	0.000238	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IRS1—osteoporosis	5.51e-05	0.000236	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—IRS2—osteoporosis	5.5e-05	0.000235	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ACP5—osteoporosis	5.49e-05	0.000235	CbGpPWpGaD
Mesalazine—CHUK—Disease—CALCA—osteoporosis	5.45e-05	0.000233	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.42e-05	0.000232	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—P4HB—osteoporosis	5.38e-05	0.00023	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	5.38e-05	0.00023	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KL—osteoporosis	5.36e-05	0.000229	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ENO1—osteoporosis	5.3e-05	0.000227	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—IRS1—osteoporosis	5.29e-05	0.000226	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	5.29e-05	0.000226	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	5.26e-05	0.000225	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTH—osteoporosis	5.23e-05	0.000224	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PSMA5—osteoporosis	5.22e-05	0.000223	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PSMA2—osteoporosis	5.22e-05	0.000223	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ACP5—osteoporosis	5.21e-05	0.000223	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6R—osteoporosis	5.18e-05	0.000221	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RAP1A—osteoporosis	5.14e-05	0.00022	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—MTHFR—osteoporosis	5.14e-05	0.00022	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TPI1—osteoporosis	5.11e-05	0.000218	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CNR2—osteoporosis	5.1e-05	0.000218	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NFATC1—osteoporosis	5.02e-05	0.000215	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IRS1—osteoporosis	5e-05	0.000214	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—DKK1—osteoporosis	4.98e-05	0.000213	CbGpPWpGaD
Mesalazine—CHUK—Disease—KL—osteoporosis	4.95e-05	0.000212	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—P4HB—osteoporosis	4.88e-05	0.000209	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KL—osteoporosis	4.86e-05	0.000208	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IL6—osteoporosis	4.86e-05	0.000208	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TPI1—osteoporosis	4.84e-05	0.000207	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—P4HB—osteoporosis	4.8e-05	0.000205	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—IRS1—osteoporosis	4.8e-05	0.000205	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—WNT1—osteoporosis	4.8e-05	0.000205	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—IDH2—osteoporosis	4.77e-05	0.000204	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—VDR—osteoporosis	4.76e-05	0.000204	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTH—osteoporosis	4.75e-05	0.000203	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GAPDH—osteoporosis	4.71e-05	0.000202	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6R—osteoporosis	4.69e-05	0.000201	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGA—osteoporosis	4.67e-05	0.0002	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RAP1A—osteoporosis	4.66e-05	0.0002	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CNR2—osteoporosis	4.63e-05	0.000198	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—RAP1A—osteoporosis	4.59e-05	0.000196	CbGpPWpGaD
Mesalazine—PTGS2—Disease—P4HB—osteoporosis	4.55e-05	0.000195	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NFATC1—osteoporosis	4.55e-05	0.000195	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—DKK1—osteoporosis	4.51e-05	0.000193	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP27A1—osteoporosis	4.48e-05	0.000192	CbGpPWpGaD
Mesalazine—PTGS2—Disease—GAPDH—osteoporosis	4.47e-05	0.000191	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	4.4e-05	0.000188	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	4.39e-05	0.000188	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ACP5—osteoporosis	4.36e-05	0.000187	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—WNT1—osteoporosis	4.35e-05	0.000186	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTHLH—osteoporosis	4.34e-05	0.000186	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BMP2—osteoporosis	4.34e-05	0.000186	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	4.31e-05	0.000184	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NFATC1—osteoporosis	4.25e-05	0.000182	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGB—osteoporosis	4.24e-05	0.000182	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP19A1—osteoporosis	4.23e-05	0.000181	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGA—osteoporosis	4.23e-05	0.000181	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AGER—osteoporosis	4.22e-05	0.00018	CbGpPWpGaD
Mesalazine—PTGS2—Disease—DKK1—osteoporosis	4.21e-05	0.00018	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ADCY5—osteoporosis	4.2e-05	0.00018	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—POMC—osteoporosis	4.11e-05	0.000176	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL6—osteoporosis	4.11e-05	0.000176	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	4.1e-05	0.000175	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PSMA2—osteoporosis	4.1e-05	0.000175	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PSMA5—osteoporosis	4.1e-05	0.000175	CbGpPWpGaD
Mesalazine—PTGS2—Disease—WNT1—osteoporosis	4.06e-05	0.000174	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TPI1—osteoporosis	4.05e-05	0.000173	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—IL6—osteoporosis	4.04e-05	0.000173	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4e-05	0.000171	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGA—osteoporosis	3.95e-05	0.000169	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTHLH—osteoporosis	3.93e-05	0.000168	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BMP2—osteoporosis	3.93e-05	0.000168	CbGpPWpGaD
Mesalazine—PPARG—Generic Transcription Pathway—MYC—osteoporosis	3.93e-05	0.000168	CbGpPWpGaD
Mesalazine—CHUK—Disease—ADCY5—osteoporosis	3.88e-05	0.000166	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGB—osteoporosis	3.85e-05	0.000165	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AGER—osteoporosis	3.82e-05	0.000164	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CALCA—osteoporosis	3.82e-05	0.000163	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—P4HB—osteoporosis	3.81e-05	0.000163	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ADCY5—osteoporosis	3.81e-05	0.000163	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GAPDH—osteoporosis	3.74e-05	0.00016	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL6—osteoporosis	3.73e-05	0.000159	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PSMA5—osteoporosis	3.72e-05	0.000159	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PSMA2—osteoporosis	3.72e-05	0.000159	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ENO1—osteoporosis	3.71e-05	0.000159	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TGFB1—osteoporosis	3.69e-05	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IRS2—osteoporosis	3.68e-05	0.000157	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—IL6—osteoporosis	3.67e-05	0.000157	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PSMA2—osteoporosis	3.66e-05	0.000156	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PSMA5—osteoporosis	3.66e-05	0.000156	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—RAP1A—osteoporosis	3.64e-05	0.000156	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—ESR1—osteoporosis	3.64e-05	0.000156	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTHFR—osteoporosis	3.57e-05	0.000153	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ENO1—osteoporosis	3.52e-05	0.00015	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KL—osteoporosis	3.47e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PSMA2—osteoporosis	3.47e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PSMA5—osteoporosis	3.47e-05	0.000148	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CALCA—osteoporosis	3.46e-05	0.000148	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ADCY5—osteoporosis	3.46e-05	0.000148	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GPX1—osteoporosis	3.45e-05	0.000148	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—osteoporosis	3.45e-05	0.000147	CbGpPWpGaD
Mesalazine—CHUK—Disease—IRS2—osteoporosis	3.39e-05	0.000145	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IRS2—osteoporosis	3.33e-05	0.000143	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CALCA—osteoporosis	3.23e-05	0.000138	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IRS1—osteoporosis	3.21e-05	0.000137	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—MTHFR—osteoporosis	3.18e-05	0.000136	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.18e-05	0.000136	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KL—osteoporosis	3.14e-05	0.000135	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6R—osteoporosis	3.01e-05	0.000129	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP19A1—osteoporosis	2.97e-05	0.000127	CbGpPWpGaD
Mesalazine—CHUK—Disease—IRS1—osteoporosis	2.96e-05	0.000127	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ENO1—osteoporosis	2.95e-05	0.000126	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KL—osteoporosis	2.93e-05	0.000125	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IRS1—osteoporosis	2.91e-05	0.000124	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PSMA5—osteoporosis	2.9e-05	0.000124	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PSMA2—osteoporosis	2.9e-05	0.000124	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6R—osteoporosis	2.78e-05	0.000119	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6—osteoporosis	2.78e-05	0.000119	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6R—osteoporosis	2.73e-05	0.000117	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ADCY5—osteoporosis	2.72e-05	0.000116	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SPP1—osteoporosis	2.63e-05	0.000112	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—POMC—osteoporosis	2.55e-05	0.000109	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ADCY5—osteoporosis	2.46e-05	0.000105	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ADCY5—osteoporosis	2.42e-05	0.000104	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GPX1—osteoporosis	2.42e-05	0.000103	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SPP1—osteoporosis	2.38e-05	0.000102	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IRS2—osteoporosis	2.38e-05	0.000102	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP19A1—osteoporosis	2.36e-05	0.000101	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—LEP—osteoporosis	2.33e-05	9.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—osteoporosis	2.31e-05	9.86e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ADCY5—osteoporosis	2.3e-05	9.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL1B—osteoporosis	2.29e-05	9.81e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MTHFR—osteoporosis	2.23e-05	9.54e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ESR1—osteoporosis	2.22e-05	9.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IRS2—osteoporosis	2.15e-05	9.22e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTHFR—osteoporosis	2.11e-05	9.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LEP—osteoporosis	2.11e-05	9.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—osteoporosis	2.09e-05	8.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1B—osteoporosis	2.08e-05	8.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IRS1—osteoporosis	2.07e-05	8.88e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ESR1—osteoporosis	2.01e-05	8.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IRS2—osteoporosis	2.01e-05	8.6e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—POMC—osteoporosis	2e-05	8.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6R—osteoporosis	1.95e-05	8.34e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ADCY5—osteoporosis	1.92e-05	8.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1—osteoporosis	1.92e-05	8.22e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GPX1—osteoporosis	1.92e-05	8.2e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—osteoporosis	1.89e-05	8.09e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IRS1—osteoporosis	1.88e-05	8.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—POMC—osteoporosis	1.81e-05	7.75e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—POMC—osteoporosis	1.78e-05	7.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MTHFR—osteoporosis	1.77e-05	7.57e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6R—osteoporosis	1.77e-05	7.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IRS1—osteoporosis	1.75e-05	7.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1—osteoporosis	1.74e-05	7.46e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—osteoporosis	1.65e-05	7.06e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6R—osteoporosis	1.65e-05	7.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFB1—osteoporosis	1.65e-05	7.04e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—POMC—osteoporosis	1.42e-05	6.06e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—osteoporosis	1.34e-05	5.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—osteoporosis	1.24e-05	5.3e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—osteoporosis	1.22e-05	5.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—osteoporosis	1.15e-05	4.94e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFB1—osteoporosis	1.15e-05	4.93e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—osteoporosis	1.05e-05	4.48e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFB1—osteoporosis	1.04e-05	4.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—osteoporosis	9.77e-06	4.18e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFB1—osteoporosis	9.75e-06	4.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—osteoporosis	8.68e-06	3.71e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—osteoporosis	7.87e-06	3.37e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—osteoporosis	7.34e-06	3.14e-05	CbGpPWpGaD
